Skip to main content

Table 3 Predicted summary statistics (median [min–max]) of atezolizumab exposure metrics

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Metric Observation Body weight dose (<  18 years) Flat dose (≥ 18 years)
<  30 kg
n = 23
30 to < 45 kg
n = 21
≥ 45 kg
n = 25
<  57 kg
n = 6
57 to < 65 kg
n = 6
≥ 65 kg
n = 6
Cmax, μg/mL Cycle 1 270 [182–349] 330 [232–375] 349 [281–407] 492 [303–541] 486 [419–549] 326 [243–390]
Steady-state 400 [277–517] 463 [257–585] 460 [319–618] 664 [377–764] 651 [505–868] 404 [334–540]
Cmin, μg/mL Cycle 1 55.6 [28.1–82.0] 65.0 [20.7–91.9] 65.5 [27.4–108] 97.3 [47.4–122] 98.8 [56.9–151] 57.6 [28.4–87.5]
Steady-state 120 [77.0–181] 125 [25.4–246] 112 [37.9–211] 171 [74.1–225] 164 [86.2–319] 88.1 [32.4–149]
AUC, μg*day/mL Cycle 1 2085 [1089–3053] 2757 [1471–3312] 2988 [1975–3954] 4268 [2396–4845] 4330 [3175–5448] 2733 [2306–3701]
Steady-state 4045 [2536–5695] 4781 [1730–7295] 4510 [2417–7126] 6692 [3365–8125] 6574 [4276–10,405] 3861 [2593–5774]
CL, mL/day/kg 3.72 [2.62–5.89] 3.20 [2.06–8.67] 3.15 [2.90–6.10] 3.62 [2.61–5.20] 2.90 [1.99–4.92] 3.25 [1.70–5.16]
  1. Abbreviations: AUC Area under the curve, Cmax Maximum concentration, Cmin Minimum concentration, CL Clearance